Abstral and Amitiza drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Abstral and Amitiza. Common interactions include dehydration among females and malignant neoplasm progression among males.

The phase IV clinical study analyzes what interactions people who take Abstral and Amitiza have. It is created by eHealthMe based on reports of 16 people who take Abstral and Amitiza from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Apr, 02, 2023

16 people who take Abstral and Amitiza together, and have interactions are studied.

What is Abstral?

Abstral has active ingredients of fentanyl citrate. eHealthMe is studying from 1,120 Abstral users for its effectiveness, alternative drugs and more.

What is Amitiza?

Amitiza has active ingredients of lubiprostone. It is often used in constipation. eHealthMe is studying from 9,589 Amitiza users for its effectiveness, alternative drugs and more.

Number of Abstral and Amitiza reports submitted per year:

Common Abstral and Amitiza drug interactions by gender *:

female:

Dehydration
Diarrhoea
Hypoparathyroidism
Hypophagia
Liver disorder
Malaise
Malnutrition
Nausea
Palmar-plantar erythrodysaesthesia syndrome
Paronychia

male:

Malignant neoplasm progression
Optic nerve disorder
Disseminated intravascular coagulation
Electrocardiogram qt prolonged
Lung neoplasm malignant
Metastases to bone
Myoclonus
Osteonecrosis of jaw
Rhabdomyolysis

Common Abstral and Amitiza drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Abdominal distension
Ileus

40-49:

Electrocardiogram qt prolonged
Lung neoplasm malignant
Myoclonus

50-59:

Diarrhoea
Hypoparathyroidism
Hypophagia
Liver disorder
Malaise
Malnutrition
Nausea
Palmar-plantar erythrodysaesthesia syndrome
Paronychia
Stomatitis

60+:

Malignant neoplasm progression
Optic nerve disorder
Anaemia
Disseminated intravascular coagulation
Metastases to bone
Osteonecrosis of jaw
Pleural mesothelioma malignant
Rhabdomyolysis

Common conditions people have *:

Cancer Pain: 6 people, 37.50%
Pain: 4 people, 25.00%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 4 people, 25.00%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 3 people, 18.75%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 2 people, 12.50%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 2 people, 12.50%
Rectal Cancer Stage Iii (rectal cancer has spread to lymph nodes, but has not been carried to distant parts of the body): 1 person, 6.25%
Neuropathy Peripheral (surface nerve damage): 1 person, 6.25%
Malignant Ascites (a condition in which a person with cancer has an accumulation of fluid in the abdomen): 1 person, 6.25%
Lymphoedema (localized fluid retention and tissue swelling): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Abstral and Amitiza?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Abstral (1,120 reports)
Amitiza (9,589 reports)